Wall Street analysts expect Health Catalyst (NASDAQ:HCAT) to announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Health Catalyst’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.33). The company is scheduled to report its next earnings report on Tuesday, February 11th.
On average, analysts expect that Health Catalyst will report full year earnings of ($1.13) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.02). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.04) to ($0.86). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Health Catalyst.
Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $39.40 million for the quarter, compared to analysts’ expectations of $37.77 million. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year.
Shares of Health Catalyst stock traded down $1.33 during trading on Friday, reaching $34.26. 209,744 shares of the stock traded hands, compared to its average volume of 316,969. The firm’s fifty day moving average price is $35.28. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.24. Health Catalyst has a 52-week low of $26.00 and a 52-week high of $49.85.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC purchased a new position in Health Catalyst in the third quarter worth about $5,682,000. State Street Corp purchased a new position in Health Catalyst in the third quarter worth about $4,119,000. Nepsis Inc. purchased a new position in Health Catalyst in the third quarter worth about $3,101,000. Conestoga Capital Advisors LLC purchased a new position in Health Catalyst in the third quarter worth about $3,249,000. Finally, Millennium Management LLC purchased a new position in Health Catalyst in the third quarter worth about $735,000. Institutional investors own 45.63% of the company’s stock.
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.
See Also: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.